Related references
Note: Only part of the references are listed.An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
Maria Giuseppina Baratta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
Qiang Shao et al.
CANCER RESEARCH (2014)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Qin Feng et al.
CELL RESEARCH (2014)
Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
Suhu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
Thomas De Raedt et al.
NATURE (2014)
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
Yujie Tang et al.
NATURE MEDICINE (2014)
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
Michele Ceribelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling
Rina Kanda et al.
CANCER RESEARCH (2013)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression
Surabhi Dangi-Garimella et al.
PLOS ONE (2013)
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Alexandre Puissant et al.
CANCER DISCOVERY (2013)
BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosiss
Xiaoyan Tang et al.
MOLECULAR PHARMACOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg et al.
CLINICAL CANCER RESEARCH (2012)
Interplay between β1-Integrin and Rho Signaling Regulates Differential Scattering and Motility of Pancreatic Cancer Cells by Snail and Slug Proteins
Mario A. Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Contribution of Epithelial-to-Mesenchymal Transition and Cancer Stem Cells to Pancreatic Cancer Progression
Seth B. Krantz et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
Adam D. Steg et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair
K. Kudo et al.
ONCOGENE (2012)
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
William W. Lockwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Relja Popovic et al.
CANCER DISCOVERY (2012)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2
Surabhi Dangi-Garimella et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Pancreatic Cancer Cells Respond to Type I Collagen by Inducing Snail Expression to Promote Membrane Type 1 Matrix Metalloproteinase-dependent Collagen Invasion
Mario A. Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists
Xiuwei H. Yang et al.
CANCER RESEARCH (2010)
Rho-ROCK-Myosin Signaling Meditates Membrane Type 1 Matrix Metalloproteinase-induced Cellular Aggregation of Keratinocytes
Surabhi Dangi-Garimella et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Peter Olson et al.
GENES & DEVELOPMENT (2009)
Cloning of the Human GLI2 Promoter TRANSCRIPTIONAL ACTIVATION BY TRANSFORMING GROWTH FACTOR-β VIA SMAD3/β-CATENIN COOPERATION
Sylviane Dennler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
Wu Huanwen et al.
MOLECULAR CANCER (2009)
The High Mobility Group Protein HMGA2: A Co-Regulator of Chromatin Structure and Pluripotency in Stem Cells?
Kurt Pfannkuche et al.
STEM CELL REVIEWS AND REPORTS (2009)
GL12 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer
Shintaro Narita et al.
CLINICAL CANCER RESEARCH (2008)
Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis
E. Kump et al.
ONCOGENE (2008)
The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene
Ling Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N. Shah et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells
Youngsoo Kim et al.
CANCER RESEARCH (2007)
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis
Jennifer P. Morton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
Anthony D. Yang et al.
CLINICAL CANCER RESEARCH (2006)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Activation of the BCL2 promoter in response to hedgehog/GLI signal transduction is predominantly mediated by GLI2
G Regl et al.
CANCER RESEARCH (2004)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
F Aoudjit et al.
ONCOGENE (2001)